Rocket Doctor AI Posts 56% U.S. Patient Visit Surge, Eyes Record Revenue

  • Rocket Doctor AI completed 53,348 patient visits in Q3 2026, with U.S. visits surging 56% quarter-over-quarter to 6,101.
  • Canadian visits grew 24% year-over-year to 47,247, reflecting continued expansion in core markets.
  • Company expects record quarterly revenue as cash collections catch up with patient visit growth.
  • U.S. clinical hours increased 33% from Q2 2026 to 2,634, a key operational metric for scaling.

Rocket Doctor AI's strong Q3 2026 performance underscores the accelerating demand for AI-powered healthcare solutions in North America. The company's multi-payer strategy and expanding in-network coverage are critical to its long-term revenue visibility, particularly as it navigates the complexities of U.S. healthcare reimbursement. The 56% surge in U.S. patient visits highlights the operational momentum, but the ability to convert this into sustainable financial growth will depend on improving cash collections and payor relationships.

Revenue Recognition
How the timing lag between patient visits and cash collections will impact reported revenue growth.
U.S. Market Penetration
Whether the 56% quarter-over-quarter growth in U.S. visits can be sustained as the company expands in-network coverage.
Operational Scaling
The pace at which Rocket Doctor AI can convert out-of-network patients and physicians to in-network status to improve reimbursement rates.